- Home
- RLMD vs SOPH Comparison
RLMD vs SOPH Comparison
Compare RLMD & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLMD | SOPH |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.7M | 367.7M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RLMD | SOPH |
|---|---|---|
| Price | $4.08 | $4.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $9.00 | $7.00 |
| AVG Volume (30 Days) | ★ 620.1K | 196.6K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | $18.48 |
| Revenue Next Year | N/A | $16.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.24 | $2.58 |
| 52 Week High | $5.12 | $5.70 |
Technical Indicators
Market Signals| Indicator | RLMD | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 38.62 |
| Support Level | $3.81 | $4.54 |
| Resistance Level | $4.56 | $4.85 |
| Average True Range (ATR) | 0.35 | 0.29 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 68.39 | 1.79 |
Price Performance
Historical ComparisonAbout RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.